The findings, presented at the Association for Research in Vision and Ophthalmology (ARVO) annual meeting in Denver, Colorado, suggested treatment benefits of Izervay increased over time.1 In the GATHER1 study, patients received Izervay every month (EM) or sham for 18 months. In the GATHER2 trial, patients were given Izervay EM or sham for 12 months, after which they were re-randomised to Izervay EM or every other month (EOM) up to 24 months.